8-K: CAMP4 & GSK Forge Alliance for RNA-Based Therapeutics

CAMP4 Therapeutics and GSK have entered a strategic collaboration to develop antisense oligonucleotide (ASO) therapeutics for neurodegenerative and kidney diseases, with CAMP4 receiving an upfront payment and potential milestones.

Summary

• CAMP4 Therapeutics Corporation entered into a Research, Collaboration and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK) on December 17, 2025.
• The collaboration focuses on the research and development of antisense oligonucleotide (ASO) therapeutics targeting regulatory RNAs associated with multiple gene targets relevant to neurodegenerative and kidney disease indications.
• The agreement combines CAMP4's proprietary regRNA mapping and ASO discovery platform with GSK's global development and commercial capabilities.
• CAMP4 has granted GSK an exclusive, worldwide license under certain patents and know-how to research, develop, manufacture, and commercialize compounds and products directed to the Collaboration Targets.
• CAMP4 will conduct research activities to identify, validate, and deliver lead ASO series and transfer related data packages and know-how to GSK.
• GSK will assume sole responsibility for development, regulatory activities, manufacturing, and commercialization of licensed compounds and products globally after CAMP4's research activities.
• CAMP4 will receive a one-time, non-refundable upfront payment of $17.5 million.
• CAMP4 is eligible to receive up to $440 million in development and commercial milestone payments, subject to achievement of specified criteria.
• CAMP4 is also eligible for tiered royalties on annual net sales of licensed products, ranging from the lowto mid-single digits during a defined royalty term for each licensed product.
• The agreement includes customary provisions regarding governance, diligence, intellectual property ownership, confidentiality, and indemnification.
• The agreement may be terminated in its entirety or on a Collaboration Target-by-Collaboration Target basis for convenience by GSK, or by either party under certain other circumstances, including material breach.

Sentiment

Score: 8

Explanation: The strategic collaboration with GSK, including a substantial upfront payment and significant potential milestone payments and royalties, provides strong validation for CAMP4's platform and financial runway, while leveraging a major pharmaceutical partner's development and commercialization expertise. This significantly de-risks future development and enhances the company's prospects.

Positives

• Secured a significant strategic research, collaboration, and license agreement with a major global pharmaceutical company, GSK.
• Received a non-refundable upfront payment of $17.5 million, providing immediate capital.
• Eligible for substantial future payments, including up to $440 million in development and commercial milestones.
• Will receive tiered royalties on annual net sales of licensed products, ranging from lowto mid-single digits.
• The collaboration validates CAMP4's proprietary RAP Platform and its potential to create transformational medicines.
• Leverages GSK's global development and commercial capabilities, de-risking future development and commercialization efforts for CAMP4.

Negatives

• GSK will have sole responsibility for development, regulatory activities, manufacturing, and commercialization, meaning CAMP4 relinquishes control over these stages.
• The agreement can be terminated for convenience by GSK, introducing a degree of uncertainty regarding the long-term partnership.

Risks

• Actual results, performance, or achievements may differ materially from anticipated results due to risks, uncertainties, and contingencies.
• Limited operating history and incurrence of substantial losses since inception, with anticipation of incurring substantial and increasing losses for the foreseeable future.
• Need for substantial additional financing to achieve goals.
• Uncertainty, length, and expense of clinical development, characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, development and commercialization of product candidates.
• Delays or difficulties in the enrollment and dosing of patients in clinical trials.
• Impact of any significant adverse events or undesirable side effects caused by product candidates.
• Potential competition, including from large and specialty pharmaceutical and biotechnology companies.
• Ability to realize the benefits of current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships.
• Ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication.
• Dependence on the services of senior management and other clinical and scientific personnel, and the ability to retain these individuals or recruit additional management or clinical and scientific personnel.
• Ability to grow the organization, and manage growth and expansion of operations.
• Risks related to the manufacturing of product candidates, which is complex, and the risk that third-party manufacturers may encounter difficulties in production.
• Ability to obtain and maintain sufficient intellectual property protection for current and future products.
• Reliance on third parties to conduct preclinical studies and clinical trials.
• Compliance with obligations under the licenses granted to the company by others, for the rights to develop and commercialize product candidates.
• Risks related to the operations of suppliers.
• Other risks and uncertainties described in the section Risk Factors in the Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

Future Outlook

The collaboration aims to accelerate the development of novel antisense oligonucleotide (ASO) therapeutics for neurodegenerative and kidney diseases by leveraging CAMP4's proprietary RAP Platform. CAMP4 anticipates receiving future contingent milestones and royalties as GSK progresses with the development and commercialization of licensed products.

Management Comments

• Josh Mandel-Brehm, President and CEO of CAMP4: "Protein under-expression plays a critical role in diseases such as neurodegenerative and kidney disease. Our collaboration with GSK, focused on the rapid identification of novel targets and potential ASO therapeutics that increase the expression of validated genetic targets, underscores the potential of our discovery platform to create transformational medicines for patients."
• Chris Austin, SVP Research Technologies, GSK: "We are excited to collaborate with CAMP4, combining their RNA discovery platform to increase specific gene activity with GSKs expertise in therapeutic oligonucleotides, genetics and advanced laboratory and data technologies. This agreement aims to drive the development of novel medicines for neurodegenerative and kidney disease and demonstrates our approach of harnessing cutting-edge technologies to deliver transformational therapies for patients."

Industry Context

This collaboration highlights the growing trend of large pharmaceutical companies partnering with smaller, innovative biotech firms to access cutting-edge drug discovery platforms, particularly in the rapidly evolving field of RNA therapeutics. The focus on neurodegenerative and kidney diseases addresses areas with significant unmet medical needs. GSK's involvement provides strong validation for CAMP4's proprietary RAP Platform and its approach to upregulating gene expression, positioning the company favorably within the competitive biopharmaceutical landscape.

Comparison to Industry Standards

• The upfront payment of $17.5 million and potential milestones of up to $440 million, along with tiered royalties, are consistent with industry benchmarks for early-stage discovery and licensing agreements in the biopharmaceutical sector, especially for platform-based collaborations targeting multiple indications.
• Comparable deals in the RNA therapeutics space, such as those involving companies like Ionis Pharmaceuticals or Alnylam Pharmaceuticals, have often featured similar financial structures, with upfront payments ranging from single-digit millions to tens of millions and total potential deal values frequently exceeding several hundred million dollars, depending on the number of targets and the stage of the technology.
• The structure, where CAMP4 focuses on discovery and GSK handles later-stage development and commercialization, is a common model for biotech-pharma partnerships, allowing the biotech to monetize its platform while mitigating the high costs and risks of clinical trials and market entry.

Stakeholder Impact

• Shareholders: Positive impact due to significant non-dilutive upfront payment, potential for substantial future milestone and royalty payments, validation of the company's technology by a major pharmaceutical partner, and reduced financial risk for product development.
• Employees: Potential for increased research activity and enhanced job security due to the strategic partnership and financial infusion.
• Customers/Patients: Potential for the development of novel therapeutic options for neurodegenerative and kidney diseases, addressing significant unmet medical needs.
• Creditors: Improved financial stability and revenue prospects may enhance the company's creditworthiness.

Next Steps

• CAMP4 will conduct research activities to identify, validate, and deliver lead ASO series for the Collaboration Targets.
• CAMP4 will transfer related data packages and know-how to GSK.
• GSK will assume sole responsibility for the further development, regulatory activities, manufacturing, and commercialization of licensed compounds and products globally.
• CAMP4 intends to file the complete text of the Agreement, with confidential terms redacted, as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2025.

Key Dates

Recommendation

The strategic collaboration with GSK represents a significant validation of CAMP4's proprietary RNA-based therapeutic platform, providing a substantial non-dilutive upfront payment of $17.5 million and potential for up to $440 million in development and commercial milestones, plus tiered royalties. This partnership with a global pharmaceutical leader like GSK de-risks the development pathway for multiple gene targets in neurodegenerative and kidney diseases, leveraging GSK's extensive resources for clinical development and commercialization. For a clinical-stage biopharmaceutical company, securing such a comprehensive agreement with a major player is a strong positive signal, enhancing financial stability and increasing the probability of successful product development and market entry, making it a strong buy.

Keywords

ASO therapeutics, neurodegenerative disease, kidney disease, RNA-based therapeutics, drug discovery, biopharmaceutical, collaboration, licensing agreement, gene expression, regulatory RNA, RAP Platform, GlaxoSmithKline